JP2008517900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517900A5 JP2008517900A5 JP2007537422A JP2007537422A JP2008517900A5 JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5 JP 2007537422 A JP2007537422 A JP 2007537422A JP 2007537422 A JP2007537422 A JP 2007537422A JP 2008517900 A5 JP2008517900 A5 JP 2008517900A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- agent
- isd
- seq
- staphylococcus aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 241000191967 Staphylococcus aureus Species 0.000 claims 5
- 229960005486 vaccine Drugs 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108700002704 Staphylococcus aureus IsdB Proteins 0.000 claims 1
- 108700009673 Staphylococcus aureus IsdC Proteins 0.000 claims 1
- 101100233397 Staphylococcus aureus isdA gene Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 101150116335 isdA gene Proteins 0.000 claims 1
- 101150057984 isdB gene Proteins 0.000 claims 1
- 101150003115 isdC gene Proteins 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62192104P | 2004-10-25 | 2004-10-25 | |
| PCT/IB2005/004126 WO2006059247A2 (en) | 2004-10-25 | 2005-10-25 | VACCINES, COMPOSITIONS AND METHODS BASED ON STAPHYLOCOCCUS AUREUS IRON-REGULATED SURFACE DETERMINANTS IsdA, IsdB, and IsdC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517900A JP2008517900A (ja) | 2008-05-29 |
| JP2008517900A5 true JP2008517900A5 (enExample) | 2008-12-18 |
Family
ID=36565416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537422A Pending JP2008517900A (ja) | 2004-10-25 | 2005-10-25 | スタフィロコッカス−アウレウスＩｓｄたんぱく質ベースの抗感染薬 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1812066A4 (enExample) |
| JP (1) | JP2008517900A (enExample) |
| KR (1) | KR20070085457A (enExample) |
| AU (1) | AU2005310981A1 (enExample) |
| CA (1) | CA2581746A1 (enExample) |
| WO (1) | WO2006059247A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607323B8 (pt) | 2005-02-14 | 2021-05-25 | Epitopix Llc | composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo |
| CA2637598A1 (en) * | 2006-01-18 | 2007-02-14 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| WO2008152447A2 (en) * | 2006-10-30 | 2008-12-18 | The University Of Western Ontario | Staphylococcus aureus specific anti-infectives |
| CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| US8758765B2 (en) | 2008-07-29 | 2014-06-24 | The University Of Chicago | Compositions and methods related to Staphylococcal bacterium proteins |
| BRPI1011856A2 (pt) | 2009-03-23 | 2020-11-03 | Epitopix, Llc | polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso |
| SMT202000246T1 (it) | 2009-04-03 | 2020-07-08 | Univ Chicago | Composizioni e metodi relativi a varianti della proteina a (spa) |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| BR112013000097B1 (pt) | 2010-07-02 | 2022-02-01 | The University Of Chicago | Polipeptídeo imunogênico isolado, composição imunogênica e seu uso |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| KR20160021076A (ko) * | 2013-03-15 | 2016-02-24 | 테출론 인코포레이티드 | 스타필로코커스 아우레우스 감염의 치료를 위한 안티센스 분자 |
| US9834768B2 (en) | 2014-12-31 | 2017-12-05 | Korea Advanced Institute Of Science And Technology | Effective method for specific gene silencing using artificial small RNA |
| CN120943954A (zh) * | 2025-10-20 | 2025-11-14 | 重庆原伦生物科技有限公司 | 抗金黄色葡萄球菌IsdB抗体的制备及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| EP2320233A1 (en) * | 2001-06-15 | 2011-05-11 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| CA2808598A1 (en) * | 2001-08-02 | 2003-02-13 | University Of Sheffield | Antigenic polypeptides |
| NZ544542A (en) * | 2003-07-24 | 2009-01-31 | Merck & Co Inc | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| ES2730275T3 (es) * | 2004-09-22 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Composición inmunógena para uso en vacunación contra estafilococos |
-
2005
- 2005-10-25 CA CA002581746A patent/CA2581746A1/en not_active Abandoned
- 2005-10-25 JP JP2007537422A patent/JP2008517900A/ja active Pending
- 2005-10-25 AU AU2005310981A patent/AU2005310981A1/en not_active Abandoned
- 2005-10-25 EP EP05850805A patent/EP1812066A4/en not_active Withdrawn
- 2005-10-25 KR KR1020077011878A patent/KR20070085457A/ko not_active Withdrawn
- 2005-10-25 WO PCT/IB2005/004126 patent/WO2006059247A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517900A5 (enExample) | ||
| EP2983695B1 (en) | Methods, uses and compositions of tie2 agonists | |
| JP2008536483A5 (enExample) | ||
| JP2002542798A5 (enExample) | ||
| JP2008546390A5 (enExample) | ||
| JP2012092117A (ja) | Ｉｌ−２３活性を調節する方法；関連する試薬 | |
| JP2006519605A5 (enExample) | ||
| RU2012107993A (ru) | Полипептиды porhyromonas gingivalis | |
| JP2012522010A5 (enExample) | ||
| JP2010530238A5 (enExample) | ||
| EP3737407A1 (en) | Peptides having protease activity for use in the treatment or prevention of coronavirus infection | |
| JP2009545526A5 (enExample) | ||
| CA2693717A1 (en) | Immunology treatment for biofilms | |
| WO2022174768A1 (en) | Anti-viral peptides and compositions and methods of use thereof | |
| Lin et al. | Human cytomegalovirus and Epstein–Barr virus inhibit oral bacteria‐induced macrophage activation and phagocytosis | |
| WO2016079321A1 (en) | Antagonists of setdb2 for use in the therapy of infectious diseases | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| US9125861B2 (en) | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections | |
| Herrera et al. | The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF. 2 contributes to virulence in an influenza superinfection | |
| Zhao et al. | A broad-spectrum virus-and host-targeting antiviral peptide against SARS-CoV-2 and other respiratory viruses | |
| JP2009526861A5 (enExample) | ||
| JP2008514196A5 (enExample) | ||
| JP2008512108A5 (enExample) | ||
| US9439438B2 (en) | Methods and compositions for reducing Shiga toxin induced toxicity in mammals | |
| WO2009045434A2 (en) | Inhibitors of staphylococcus aureus sdrd protein attachment to cells and uses therefor |